The use of accelerator MS in support of MIST


“There is no doubt that AMS can provide valuable information in support of MIST, enhancing our ability to profile metabolites in early clinical studies via comprehensive detection and robust quantitation. As ever, a judgment must be made as to whether the additional burden of the AMS approach … represents a valuable investment at the early stages of drug development…” The issue of how best to underwrite the safety of metabolites formed in humans has been an important consideration within the pharmaceutical industry for many decades. Following the publication, in 2002, of a letter from the Pharmaceutical Manufacturers Association [1] that...

To view this content, please register now for access

It's completely free